MedTrace Logo

Ivermectin Nasal Spray for COVID19 Patients

NCT04510233 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-08-12

No results posted yet for this study

Summary

The global escalation of COVID19 pandemic has put the health care system under pressure with urgent need for treatment. In the absence of vaccine and approved drug against SARS-COV2 over the past 6 months, the health authorities were obliged to re-purpose existing drugs to fight this pandemic.

Conditions

  • Covid19

Interventions

DRUG

Ivermectin nasal

Ivermectin nasal spray one ml in each nostril two times daily

DRUG

Ivermectin oral

Ivermectin oral (one tablet 6 mg three times daily)

OTHER

standard care

oxygen via masks or ventilators

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Kamal Okasha, PhD · Tanta Univesity faculty of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-30
Primary Completion
2020-10-31
Completion
2020-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04510233 on ClinicalTrials.gov